financetom
Business
financetom
/
Business
/
Factbox-US banks weather Fed's annual stress test, but risks rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Factbox-US banks weather Fed's annual stress test, but risks rise
Jun 27, 2024 7:37 AM

(Reuters) - Big U.S. banks had enough capital to weather a potentially severe economic downturn but some of their risky businesses could hypothetically take a major hit this year, according to results of the Federal Reserve's annual stress test.

The 31 banks that participated showed they could withstand a spike in joblessness and stresses in the commercial real estate market and still have enough capital available to lend.

Their common equity tier 1 (CET1) ratio, a metric that gauges high-quality capital, will dip to 9.9% at its lowest, still far ahead of the 4.5% minimum requirement.

Here is how some of the biggest U.S. banks fared in the test:

Bank Minimum

common equity tier 1

(CET1) ratio

JPMorgan Chase ( JPM ) 12.5%

Bank of America ( BAC ) 9.1%

Wells Fargo 8.1%

Citigroup ( C/PN ) 9.7%

Goldman Sachs ( GS ) 8.5%

Morgan Stanley ( MS ) 10.6%

The Fed also projected losses on loans could reach up to $571 billion under its severely adverse scenario. Credit card loans could be tricky, the central bank said.

The corporate credit portfolios of banks have also shifted towards riskier loans. They now hold a larger share of non-investment grade corporate credit, which are over three times more likely to default than investment grade ones, the Fed said.

Here are the banks with the steepest potential loan losses, according to the central bank:

COMMERCIAL AND INDUSTRIAL LOANS -

Bank

Projected losses

(as % of average

loan balances)

Discover Financial 21.8%

Barclays US 19.3%

Goldman Sachs ( GS ) 16.2%

CREDIT CARDS -

Bank

Projected losses (as

% of average loan

balances)

Ally Financial ( ALLY ) 40.6%

Goldman Sachs ( GS ) 25.4%

Capital One 23.2%

COMMERCIAL REAL ESTATE LOANS -

Bank Projected loan

losses (as % of average

loan balances)

Goldman Sachs ( GS ) 15.9%

Royal Bank of Canada USA 15.8%

Capital One 14.6%

(Reporting by Niket Nishant in Bengaluru; Editing by Devika Syamnath)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
General Motors Faces Tariffs Heat, Margins Shrink
General Motors Faces Tariffs Heat, Margins Shrink
Jul 22, 2025
General Motors Company ( GM ) slumped in Tuesday’s premarket session after reporting a sharp drop in adjusted EBIT margins to 6.4% and a whopping $1.1 billion tariff headwind. The auto behemoth registered second-quarter adjusted earnings per share of $2.53, beating the analyst consensus estimate of $2.40. Quarterly sales of $47.12 billion outpaced the Street view of $45.57 billion. Net sales...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Shimmick Says It Won $51 Million Contract in California
Shimmick Says It Won $51 Million Contract in California
Jul 22, 2025
08:52 AM EDT, 07/22/2025 (MT Newswires) -- Shimmick ( SHIM ) said Tuesday it was awarded a $51 million contract by the Stockton East Water District for the Bellota Weir Modifications project in Stockton, California. Construction will likely begin in 2025 after the completion of final permitting and preconstruction activities, the company said. Shimmick ( SHIM ) shares were down...
Replimune's Melanoma Therapy Denied FDA Approval, Shares Fall Sharply
Replimune's Melanoma Therapy Denied FDA Approval, Shares Fall Sharply
Jul 22, 2025
08:53 AM EDT, 07/22/2025 (MT Newswires) -- Replimune Group ( REPL ) said Tuesday the US Food and Drug Administration has declined to approve its biologics license application for its experimental drug, RP1 combined with nivolumab, to treat advanced melanoma, citing concerns with the study. Replimune ( REPL ) shares were more than 77% lower in premarket trading. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved